Suven Pharmaceuticals Ltd
Suven Pharmaceuticals Ltd (SUVENPHAR)

Suven Pharmaceuticals Ltd (SUVENPHAR)

₹452.30.84%

Key Stats

₹447
Day's Price Range
₹456
₹425.7
52-Week Price Range
₹631.75
1 Month Return-1.64 %
3 Month Return-12.63 %
1 Year Return-18.88 %

Company Financials

  • Quarterly
  • Annual
Value in ₹ crore

Peer Comparsion

PE
Rank 164
25.17
EPS
Rank 100
₹17.83
BVPS
Rank 194
₹46.39
Dividend Yield
Rank 135
0.4%
ROE
Rank 30
33.4%
Price To Book Ratio
Rank 213
9.67
Debt To Asset
Rank 277
0.2

Company Information

Suven Pharmaceuticals Limited SPL is a biopharmaceutical company incorporated on 6th November 2018 and is engaged in the business of development and manufacturing of New Chemical Entity NCE based Intermediates Active Pharmaceutical Ingredients API Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical biotechnology and chemical companies. Suven Pharma Inc. a Delaware Company is a WOS wholly owned subsidiary of SPL is a SPV Special Purpose Vehicle created on 9th March 2019 for undertaking various business opportunities in Pharma Industry.During the year 201920 Suven Life Sciences Ltd. SLSL has transferred the CRAMS business undertaking to the Company in accordance with the Scheme of Arrangement Demerger approved by the Honble NCLT Hyderabad Bench now integrated with Contract Development and Manufacturing Operations CDMO business model of the Company. In terms of the sanctioned Scheme the Company issued and allotted 1 One fully paid up equity share of face value of Re 1/ Rupee One only each of SPL for every 1 One fully paid up equity share of face value of Re 1/ Rupee One only each held by each shareholder in the Demerged Company SLSL as on the Record Date i.e. 22nd January 2020 thereby resulted in a mirror shareholding of SLSL in the Company. The equity shares of the Company were listed to trade w.e.f. 09th March 2020.The Board of Directors in its meeting held on August 17 2020 considered approved and recommended an issue of bonus shares in the proportion of 1:1 one new equity share of the Company of Re 1 each for every one existing equity share of the Company of Re 1 each.The company has a massive Rs 320crore capex plan. Suven has invested Rs 120 crore in 201920. The balance is to be invested in 202021.During the year 201920 the Company invested USD35 million in Rising Pharma Holdings Inc. USA through its wholly owned subsidiary Suven Pharma Inc. USA. Suven Pharma Inc. in USA was originally formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period now integrated with CDMO business of the Company as per the decisions taken by the Board of the Company and of the Demerged Company i.e. Suven Life Sciences Ltd in accordance with the enabling provisions of Scheme of Arrangement as sanctioned by Honble NCLT Hyderabad Bench. As a result Suven Pharma Inc. in USA has become wholly owned subsidiary of the company during the FY 20192020.As on 31 March 2020the company has one subsidiary and one associate company under its roof.The company filed 11 ANDAs as on March 31 2020 and three of those secured the green light from the regulator.The Board has allotted the Bonus shares at 1:1 ratio in its Board Meeting held on 29 September 2020. Accordingly the number of shares increased from 127282478 to 254564956..
OrganisationSuven Pharmaceuticals Ltd
HeadquartersHyderabad
IndustryPharmaceuticals